^
    Back
    Association details:
    Biomarker:MET expression
    Cancer:Non Small Cell Lung Cancer
    Drug:REGN5093-M114 (Tubulin inhibitor, c-MET-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Published date:
    01/04/2023
    Excerpt:
    REGN5093-M114 exhibited significant antitumor efficacy compared with MET TKI or unconjugated METxMET biparatopic antibody (REGN5093). Cell surface MET expression had the most predictive power in determining the efficacy of REGN5093-M114.
    DOI:
    10.1158/1078-0432.CCR-22-2180